CAI Stock Analysis: Buy, Sell, or Hold?
CAI - Caris Life Sciences, Inc. Common Stock
$16.85
-0.10 (-0.59%)
▼
5d:
-12.51%
30d:
-16.34%
90d:
-40.32%
WAIT
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: Feb 26, 2026
0d
Get Alerted When CAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CAI is down 12.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CAI is down 12.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$18.68
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$11.60
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CAI is currently trading at $16.85, which is considered oversold relative to its 30-day fair value range of $17.87 to $19.71. From a valuation perspective, the stock is trading at a discount (Forward PE: 43.9) compared to its historical average (51.3). Remarkably, the market is currently pricing in an annual earnings decline of 5.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CAI is in a strong downtrend. Immediate support is located at $16.28, while resistance sits at $19.68.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $32.80 (+94.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CAI is in a strong downtrend. Immediate support is located at $16.28, while resistance sits at $19.68.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $32.80 (+94.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$17.87 -
$19.71
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 94.7% below Wall St target ($32.80)
- WARNING: Recommendation downgraded due to -12.5% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$17.87 -
$19.71
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$16.28
Resistance Level
$19.68
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
43.93
Wall Street Target
$32.80
(+94.7%)
Revenue Growth (YoY)
125.4%
Profit Margin
-8.4%
Valuation Discount vs History
-5.0% cheaper
PE vs Historical
43.9 vs 51.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.0%
(market-implied from PE analysis)
1-Year Target
$16.01
(-5%)
2-Year Target
$15.21
(-10%)
3-Year Target
$14.45
(-14%)
3-Yr Target (if PE normalizes)
(PE: 44→51)
$16.87
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 43.9, Growth: 155.6%)
$56.87
(+238%)
Base:
(SPY PE: 22.4, Growth: 155.6%)
$28.94
(+72%)
Bear:
(PE: 19.0, Growth: 155.6%)
$24.60
(+46%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 43.9 to 51.3
Stabilization Target:
$19.68
(+16.8%)
PE Expansion Potential:
+16.8%
Share & Embed Analysis
Last updated: March 30, 2026 6:23 PM ET
Data refreshes hourly during market hours. Next update: 7:23 PM
Data refreshes hourly during market hours. Next update: 7:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Luke Thomas Power
SELL
62250 shares
2025-12-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 56 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$873 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 45 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 60 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$224 | 57 HOLD |